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Background: Research on microRNAs (miRNAs) is becoming an increasingly attractive field, as these small RNA
molecules are involved in several physiological functions and diseases. To date, only few studies have assessed the
expression of blood miRNAs related to Parkinson’s disease (PD) using microarray and quantitative real-time PCR
(qRT-PCR). Measuring miRNA expression involves normalization of qRT-PCR data using endogenous reference genes
for calibration, but their choice remains a delicate problem with serious impact on the resulting expression levels.
The aim of the present study was to evaluate the suitability of a set of commonly used small RNAs as normalizers
and to identify which of these miRNAs might be considered reliable reference genes in qRT-PCR expression analyses
on PD blood samples.
Results: Commonly used reference genes snoRNA RNU24, snRNA RNU6B, snoRNA Z30 and miR-103a-3p were
selected from the literature. We then analyzed the effect of using these genes as reference, alone or in any possible
combination, on the measured expression levels of the target genes miR-30b-5p and miR-29a-3p, which have been
previously reported to be deregulated in PD blood samples.
Conclusions: We identified RNU24 and Z30 as a reliable and stable pair of reference genes in PD blood samples.
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MicroRNAs (miRNAs) are small non-coding RNAs of
20–22 nucleotides involved in transcriptional and post-
transcriptional regulation of gene expression. MiRNAs
function via base-pairing with complementary sequences
within target mRNA molecules, usually resulting in gene
silencing via translational repression or target degrad-
ation [1]. MiRNAs are involved in several physiological
functions, such as cell cycle, apoptosis, proliferation, dif-
ferentiation and development [2]. In recent years the re-
search on miRNAs has increased in intensity because of
their involvement not only in physiological processes
but also in different diseases. Several studies have shown* Correspondence: christine.schwienbacher@eurac.edu
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unless otherwise stated.abnormal expression levels of miRNAs in different patholo-
gies, including Parkinson’s disease [3]. The main clinical
hallmarks of this neurodegenerative disorder are resting
tremor, muscular rigidity, bradykinesia, impaired balance
and coordination. Pathologically PD is characterized by
the loss of the dopaminergic neurons in the motor control
region substantia nigra and an accumulation of protein-
filled structures called Lewy bodies [4]. Lewy bodies and
other brain specific diagnostic signs cannot be observed
until after death of the PD affected individuals. Biomarkers
from easy accessible resources, such as peripheral blood,
plasma, serum, urine, saliva, and eventually cerebrospinal
fluid could be used to detect and monitor the disease
much earlier, even before symptoms appear. Unfortunately
to date no proven biomarkers are available for the diagno-
sis of PD [5]. MiRNAs are strong and specific gene regula-
tors and therefore promising candidates to be diagnostic
markers and therapeutic targets. Peripheral blood can beLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ily obtainable and reflects dynamically a system-wide biol-
ogy [6].
To date, only few studies have assessed the expression
of blood miRNAs related to Parkinson’s disease using
microarray and quantitative real-time PCR [7,8]. Several
methods have been developed to measure miRNA ex-
pression [9]. Of these methods qRT-PCR is superior due
to its sensitivity, specificity and linear dynamic range of
quantification [10,11] and is therefore generally accepted
as the gold standard for accurate gene quantification
and small RNA profiling. To distinguish true biological
changes from technical variations, several variables must
be considered and controlled for gene-expression ana-
lysis, such as the amount of the starting material and
differences between tissues in overall transcriptional ac-
tivity. The use of multiple stable reference genes is
generally necessary as the method of choice for qRT-
PCR data normalization. The normalization procedure is
adapted to compare the expression levels of target genes
with the expression of a reference gene to obtain a rela-
tive quantification of the investigated target gene [12].
The expression of an ideal reference gene should not
vary in the tissues or cells under investigation and in re-
sponse to treatment or presence of a pathology [13]. Ac-
curate expression profiling is critically dependent on
technical variations due to the applied normalization
strategies. A misleading estimation of the expression
analysis data can arise if only a single or improper refer-
ence genes are used [14]. These stable reference genes
can be identified from a set of candidate reference genes
in a pilot experiment on a selection of samples that are
representative for the experimental conditions under in-
vestigation. Different algorithms, such as geNorm and
Normfinder allow the ranking of candidate reference
genes according to their stability and indicate the opti-
mal number and combination of reference genes re-
quired for accurate normalization of gene expression
[10]. In the case of miRNA expression profiling, only
few candidate reference miRNAs, including miRNA 103,
have been identified [15,16]. Typically, other small en-
dogenous noncoding RNAs such as small nuclear
(snRNAs) and small nucleolar RNAs (snoRNAs) have
been used [10] as they share similar properties, such as
RNA stability and size and are expressed abundantly.
Unfortunately their expression is not always stable
[17]. As no universal reference gene has so far been
identified, there is no substitute for empirical valid-
ation of normalization that is appropriate to the par-
ticular experimental design and goals [16]. Recently
expression studies of circulating miRNAs in serum or
plasma as potential biomarkers for PD are emerging
[18,19]. In these studies synthetic, non-human spike-in
miRNAs, used frequently to monitor RNA purificationand retrotranscription efficiencies, are almost exclu-
sively used as well for normalization in expression ana-
lyses, because of the lack of established reference genes
[9]. Moreover, new emerging technologies including
Droplet Digital PCR technology, which provides an abso-
lute quantification of nucleic acids, are trying to overcome
the problem of the normalization, but for now they are
available only in few laboratories.
The aim of the present study was to evaluate the suit-
ability of a set of commonly used small RNAs as nor-
malizers and to identify which of these miRNAs might
be considered reliable reference genes in qRT-PCR ex-
pression analyses on PD blood samples. We compared
the potential reference genes, snoRNA RNU24 (RNU24),
snRNA RNU6B (RNU6B), snoRNA Z30 (Z30) and miR-
103a-3p to find the best set of reference genes to use for
normalization using (i) comparative delta-Ct [20], (ii)
the NormFinder algorithm [21] and (iii) qbasePLUS, an
improved version of the geNorm algorithm [14]. The ef-
fect of different reference genes used on the relative
quantification was shown using the target genes miR-
30b-5p and miR-29a-3p, previously shown to be differ-
entially expressed in PD blood samples [7,8].
Methods
Patient and control samples collection
38 patients affected by idiopathic Parkinson’s disease
(PD) attending the Movement Disorders outpatient clinic
of the Bolzano Hospital (Italy) were enrolled. Diagnosis
of PD was made according to Gelb PD criteria [22]. All
the patients were treated with Levodopa. The subjects
with cognitive impairment or unable to sign informed
consent or affected by atypical Parkinsonism were ex-
cluded. 38 disease-free controls matched for sex and age
(range ± 3 years), collected among spouses or unrelated
companions of the patients, were also enrolled. The
study was approved by the ethics committee of the Bol-
zano Hospital and all of the enrolled subjects provided
written informed consent to participate.
RNA isolation and quality control
Whole peripheral blood from patients and controls was
collected per participant in a Na3-Citrate buffered Veno-
safe® Plastic Tube (VF-054SBCS07, Terumo) and stored
at room temperature. Within 6 hours of blood collection
the peripheral blood mononuclear cells (PBMCs) were
isolated after lysis of red blood cells by Red Blood Cell
(RBC) Lysing Buffer. Total RNA, including small RNAs,
was extracted from white blood cells using TRIzol® reagent
(Invitrogen) according to the manufacturer’s instructions
and stored at −80°C.
The quality and quantity of the extracted RNA was
assessed by agarose gel electrophoresis and by Experion™
Automated Electrophoresis System (Bio-Rad Laboratories
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(Bio-Rad Laboratories s.r.l., Milano, Italy). The RNA Qual-
ity Indicator (RQI) feature of Experion software allows es-
timating the level of the integrity of eukaryotic total RNA
samples. All 76 collected samples showed an a RQI ≥ 8.0
and were included in the expression analyses.
Reverse Transcription and gene specific quantitative real
time PCR
Expression analyses were performed by single gene specific
stem loop RT-PCR. Reverse transcription (RT) reactions
were performed on 7 ng of total RNA using the TaqMan
miRNA Reverse Transcription Kit (Applied Biosystem;
Part.No 4366597) and miRNA-specific stem-loop primers
(Table 1) in a scaled down volume of 10 μl RT reaction,
according to the manufacturer’s instructions.
The thermal cycling parameters of reverse transcrip-
tion were 30 min at 16°C, 30 min at 42°C, and 5 min at
85°C. The cDNA samples were diluted in nuclease-free
water and stored at −20°C.
All quantitative real-time PCR reactions were performed
in triplicate on Bio-Rad 96CFX instrument (Bio-Rad
Laboratories s.r.l., Milano, Italy), in scaled down 10 μl reac-
tion volumes using 0.7 μl of RT product per reaction using
Universal MasterMixII, no UNG and gene specific
TaqMan® small RNA Assays (Applied Biosystem®; Table 1)
according to the manufacturer’s instructions. All reactions
were performed on hard shell PCR plates (Bio-Rad Labora-
tories Inc. Part.No HSP9645), sealed using adhesive Micro-
seal ‘B’ Films (Bio-Rad Laboratories Inc. Part.No RSN
102595). One reference sample and one NTC (blank) were
included in triplicate on each plate. The thermal cycling
parameters were 10 min at 95°C followed by 40 cycles of
15 sec at 95°C and 1 min at 60°C.
PCR amplification efficiencies for all target and reference
genes were determined from the slope of the log-linear
portion of calibration curves, generated from a two-fold
dilution series of one reference sample at five dilution
points for three technical replicates for each gene assay





hsa-miR-30b-5p MIMAT0000420 602 UGUAAACA
hsa-miR-29a-3p MIMAT0000086 2112 UAGCACCAU
hsa-miR-103a-3p MIMAT0000101 439 AGCAGCAUU
RNU24 NR_002447 1001 AUUUGCUAU
GACAUUUUAAACC
Z30 AJ007733 1092 UGGUAUUGCCAUUG
CAGGGUAUGAUCUC
RNU6B NR_002752 1093 CGCAAGGAUGACACGCAAA
Gene name and relative TaqMan® MicroRNA Assays, sequence, standard curve PCRpreviously for the quantitative real-time PCR reactions.
The relative expression of miR-30b-5p and miR-29a-3p
were assessed using the Bio-Rad CFX Manager v1.6
(Bio-Rad Laboratories s.r.l., Milano, Italy) software.
For normalization, different combinations of reference
genes among RNU24, RNU6B, Z30 and miR-103a-3p
were used.Statistical analysis
In order to determine the expression stability of the four
candidate reference genes, statistical analyses of their ex-
pression across all samples were performed using three
different algorithms: NormFinder [21], GeNorm [14],
and comparative delta-Ct method [20]. NormFinder
computes a stability measure and the lowest value indi-
cates the most stable gene expression. Samples are
grouped to allow direct estimation of expression vari-
ation, ranking genes according to the similarity of their
expression profiles by using a model-based approach.
NormFinder takes into account inter- and intragroup
variation for normalization factor calculations avoiding
misinterpretation caused by artificial selection of co-
regulated genes. GeNorm computes an M value describing
the variation of a gene compared to all other candidate
genes. Similarly to the NormFinder stability value, lower
M values indicate stable gene expression. Specifically,
stable reference genes are supposed to have an M value
smaller than 1.5.
Comparative delta-Ct compares relative expression of
pairs of genes within each sample set and ranks stability
of reference genes according to the repeatability of the
gene expression difference.
Scatter plots and box plots were used to visualize the
presence of outliers in the expression Ct values; outlier
values, as evidenced by the box plot, were labelled for
possible subsequent removal. Medians and interquartile
ranges were produced to summarize data. The medians
were calculated on the differences of the expression be-
tween each case and its matched control.efficiencies














amplification efficiency and r2, the standard curve correlation coefficient.
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the difference of the expression levels between cases
and controls, within each matched pair and normalized
with different combinations of reference genes, was
checked using a Skewness-Kurtosis test for normality.
A subset of the ladder of powers for variable trans-
formation in case of departure from normality was
evaluated [23].
Relative expression of miR-29a-3p and miR-30b-5p
was analysed using a Wilcoxon matched-pairs signed-
ranks test. Although 15 tests for each microRNA were
performed, no adjustment for multiple comparisons was
done. This is because in practice the only test that would
have been performed is the one based on data a priori
normalized for the best reference gene combination.
Spearman’s rank correlation coefficients were com-
puted on Ct reference gene data and on normalized miR-
29a-3p and miR-30b-5p data. GeNorm analysis was per-
formed using Biogazelle’s qbasePLUS software (Bio-Rad
Laboratories Inc.) and NormFinder analysis was per-
formed using “NormFinder.xla”, a Microsoft Excel-based
Visual Basic application. All other analyses were performed
using Stata 12 [24].
Results
The selection of the best set of endogenous reference
genes for gene expression studies in Parkinson’s disease
blood samples was based on the efficiency of the TaqMan®
MicroRNA Assays, the quality of the related expression
data, and on the expression stability analysis.
Evaluation of the amplification efficiencies of the
TaqMan® MicroRNA Assays
The hallmarks for an accurate and optimized qRT-PCR
assay are a linear correlation coefficient (r2) equal or
greater than 0.98 and a PCR amplification efficiency






Figure 1 Expression levels in analysed genes. Box plot of raw Ct values
interquartile range, central line is the median; Whiskers: upper and lower adquality of the fit of the standard curve to the plotted
data points. Primer efficiency indicates the amplicon
doubling rate of a specific primer pair during a PCR.
An efficiency of 100% indicates that the cDNA target is
duplicated at every PCR cycle during the exponential
phase. The efficiencies of the TaqMan® MicroRNA As-
says of the four candidate reference genes (RNU24,
RNU6B, Z30 and miR-103a-3p), and the two target
genes (miR-30b-5p and miR-29a-3p) were calculated
from the slope of the log-linear portion of calibration
curves as described (Materials and Methods; Reverse
Transcription and quantitative real time PCR) and are
reported in Table 1. RNU24, Z30, miR-103a-3p, miR-
30b-5p, and miR-29a-3p showed amplification efficien-
cies and r2 values ranging respectively between 90.4%
and 97.5% and between 0.92 and 0.99 demonstrating a
high performance. In contrast, RNU6B showed a low
amplification efficiency of 79.9% with a correlation
coefficient of 0.967.Data quality control
The analysis of the generated Ct data revealed the pres-
ence of a few outliers, as evidenced in Figure 1. Because
no evident technical reason could be found to exclude
them, given the high quality of the extracted RNA as
evaluated by Experion RNA chip electrophoresis, and
the overall high performance of the qRT-PCR reactions,
they were not removed from the analyses, but they were
rather considered an expression of normal biological
variability. The differences of the relative gene expres-
sion in cases and in controls, within each matched pair,
did not always follow a normal distribution. Since no
unique transformation was able to restore deviations
from normality, a non-parametric Wilcoxon matched-
pairs signed-ranks test was subsequently used to analyse
data.miR-103a-3p miR-29a-3p miR-30b-5p
to inspect the data. y axis: Ct values; x axis: miRNAs analyzed. Boxes:
jacent values; Dots: outside values.
Table 3 Comparison of the stability values estimated
using the comparative delta-Ct, NormFinder and GeNorm
algoritms
Gene Comparative delta-Ct NormFinder GeNorm
RNU24 0.93 0.007 0.839
Z30 0.93 0.016 0.841
RNU6B 1.25 0.033 1.112
miR-103a-3p 1.34 0.018 1.310
Comparative delta-Ct =mean of the standard deviations (SD), as shown in
Table 2; NormFinder = stability values computed with NormFinder and
GeNorm: M stability values, calculated assuming the specific efficiency for each
gene assay. NormFinder = stability values computed with NormFinder and
GeNorm: M stability values, calculated assuming the specific efficiency for each
gene assay.
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The results of the expression stability assessment of Z30,
RNU24, RNU6B and miR-103a-3p genes among all ana-
lysed samples are reported in Tables 2 and 3, showing
the results of the comparative delta-Ct method, and the
comparison with the NormFinder and geNorm results.
Independently from the method used, the gene ranking
remained unchanged, indicating Z30 and RNU24 as the
best reference genes. In particular, the combination of
Z30 and RNU24 was selected as the best among all the
others, as underlined by the stability value of 0.011 cal-
culated by NormFinder, the M value of 0.489 calculated
by geNorm (see Additional file 1: Figure S1), and the
delta-Ct values (Table 2). This combination showed
the smallest and therefore best stability values among all
the other combinations of reference genes (see Additional
file 1: Figure S1) whereas the worst combination was at-
tributed to RNU6B and miR-103a-3p.
Unexpectedly, miR-103a-3p, previously indicated as a
suitable reference gene for quantification of microRNAs
in peripheral blood of PD patients through qRT-PCR
[8], was consistently found to be the worst reference
gene in the analysed sample (Tables 2 and 3).
Furthermore, since the expression of reference genes
is supposed to remain constant among different samples,
we would expect that the relationship between the expres-
sion of two reference genes is linear.
To estimate the inter-gene relations of the four puta-
tive reference genes, correlation analysis was performed.
Results indicate that the strength of the linear relation-
ship is good for Z30 and RNU24 expression (r = 0.8004,
p < 0.0001), which are those candidates ranked as the
best reference genes. The correlation of the expressionTable 2 Comparison of candidate reference genes
expression stability using the comparative delta-Ct
method
Combination Mean delta-Ct SD Mean SD
RNU24 vs Z30 −1.53 0.58 0.93
RNU24 vs RNU6B −2.26 1.09
RNU24 vs miR-103a-3p −0.71 1.12
Z30 vs RNU24 1.53 0.58 0.93
Z30 vs RNU6B −0.73 0.99
Z30 vs miR-103a-3p 0.82 1.23
RNU6B vs Z30 0.73 0.99 1.25
RNU6B vs RNU24 2.26 1.09
RNU6B vs miR-103a-3p 1.62 1.66
miR-103a-3p vs Z30 −0.82 1.23 1.34
miR-103a-3p vs RNU24 0.71 1.12
miR-103a-3p vs RNU6B −1.62 1.66
Mean delta-Ct = Ct target – Ct reference; SD = standard deviation of the mean;
mean SD =mean of the calculated standard deviations.of RNU6B and miR-103a-3p with Z30 and RNU24 is
smaller, with the lowest correlations observed between
the expression levels of miR-103a-3p and the remaining
reference genes (see Additional file 1: Table S1).
The same trend is also indicated by the scatter plot
matrix (see Additional file 1: Figure S2), where the most
linear relationship could be observed between Z30 and
RNU24.
All the analyses were also repeated excluding outlier
samples (sensitivity analyses), but no difference in the rank
of the reference genes was observed (data not shown).
Consequence of normalizing expression of miR-29a-3p
and miR-30b-5p in PD cases and matched controls with
different combinations of reference genes
We tested the effect of using different combinations of
reference genes on the relative expression values using
miR-29a-3p and miR-30b-5p as targets, which were found
to be deregulated in PD in previous studies [7,8].
The results of the Wilcoxon matched-pairs signed-
ranks test (Table 4) show that there is an increased relative
expression of miR-29a-3p and miR-30b-5p in patients
with PD in comparison to controls.
Normalizing the expression values of miR-29a-3p and
miR-30b-5p for the best reference gene combination of
Z30 and RNU24 results in a median difference of the
relative expression of 0.68 (IQR = −0.17; 1.74) for miR-
29a-3p (p value = 0.0032), and equal to 1.74 (IQR = 0.05;
4.26) for miR-30b-5p (p value =0.0009). This trend was
consistently observed using Z30, RNU24 and RNU6B as
reference genes, either alone or in different combinations
(Table 4).
However, the normalization of the microRNA expres-
sion using miR-103a-3p as reference gene results in an
opposite effect, with a lower expression of miR-29a-3p
and miR-30b-5p in cases, in comparison with controls.
The usage of miR-103a-3p alone as a reference gene was
sufficient to completely reverse the direction of the
expression difference between cases and controls of the
investigated miRNAs (miR-29a-3p median difference =−0.58,
Table 4 Changes in the results of the analyses depending on the choice of the reference genes
Reference gene miR-29a-3p median of
difference (IQR)
P value miR-29a-3p miR-30b-5p median of
difference (IQR)
P value miR-30b-5p
Z30 0.76 (−0.23; 2.22) 0.0048 1.75 (0.17; 3.62) 0.0007
RNU24 0.39 (−0.08; 1.34) 0.0151 0.96 (−0.52; 3.39) 0.0075
RNU6B 0.98 (−0.17; 2.12) 0.0007 2.66 (0.2; 4.05) 0.0001
miR-103a-3p −0.58 (−1.33; −0.05) 0.0003 −1.16 (−2.53; 0.23) 0.0005
Z30- miR-103a-3p −0.02 (−0.65; 0.6) 0.7997 0.01 (−1.14; 1.32) 0.8221
Z30-RNU24* 0.68 (−0.17; 1.74) 0.0032 1.74 (0.05; 4.26) 0.0009
Z30-RNU24- miR-103a-3p 0.18 (−0.48; 0.71) 0.5473 0.22 (−1.1; 1.63) 0.3422
Z30-RNU24-RNU6B- miR-103a-3p 0.38 (−0.31; 1.23) 0.0511 1.05 (−0.31; 2.41) 0.0092
RNU24-RNU6B 0.85 (−0.02; 1.77) 0.0011 2.37 (0.2; 3.47) 0.0004
RNU24- miR-103a-3p −0.35 (−0.75; 0.15) 0.0645 −0.7 (−1.54; 1.13) 0.2372
RNU24-RNU6B- miR-103a-3p 0.12 (−0.31; 0.91) 0.2097 0.61 (−0.44; 1.95) 0.0494
RNU24-RNU6B-Z30 0.74 (−0.08; 1.86) 0.0013 2.02 (0.1; 3.95) 0.0003
RNU6B- miR-103a-3p 0.04 (−0.41; 0.66) 0.3962 0.51 (−0.4; 1.19) 0.0939
RNU6B-Z30 0.79 (−0.1; 1.98) 0.0011 2.44 (0.17; 3.8) 0.0003
RNU6B-Z30- miR-103a-3p 0.31 (−0.36; 1.01) 0.0733 1.02 (−0.3; 1.99) 0.0119
Different combinations of reference genes lead to different relative expression values of miR-29a-3p and miR-30b-5 in the matched PD pairs, therefore affecting
the results of the statistical analyses and leading to discordant evidence. *Best set of reference genes.
The median of difference is calculated as median (expression in cases – expression in controls) within each matched case–control set and it is indicated for a
descriptive purpose. IQR = interquartile range. P values were computed using a Wilcoxon matched-pairs signed-ranks test.
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The inclusion of miR-103a-3p in any other combination
of reference genes systematically worsened the observed
p values. This effect was clearly visible with the addition
of miR-103a-3p to the combination of Z30 and RNU24,
which had a strong impact on the results observed for
both miR-29a-3p and miR-30b-5p, with the p value of
miR-29a-3p changing from p = 0.0032 to p = 0.5473 and
the p value of miR-30b-5p changing from p = 0.0009 to
p = 0.3422. Indeed, the relative expression levels of miR-
29a-3p/miR-30b-5p were not always well correlated with
each other. But some differences could be observed, de-
pending on the reference gene set used for normalization,
as shown in Additional file 1: Tables S2 and S3. Smaller
correlation coefficients could be observed when miR-
103a-3p alone was used as a reference gene, while cor-
relations were improved when it was present in other
combinations.
Sensitivity analyses were finally repeated excluding out-
lier samples, but no difference in the results was observed
(data not shown).
Discussion
Quantitative real-time PCR is the most commonly avail-
able and reliable method used in expression profile studies
aimed at detecting changes in gene expression, because
alternative approaches do not yet match the sensitivityand specificity of PCR-based approach. The choice of
housekeeping genes in a qRT-PCR study is a critical
step before starting any experiment, in order to avoid
inaccurate interpretation of the data that may lead to
biased results. Indeed, it has been shown in several
publications that traditional reference genes used in
qRT-PCR studies do not always show a stable expression
pattern. The same gene revealed as almost invariant for
certain tissues or cell types, could present highly variable
expression levels in other tissues or experimental condi-
tions [20,25,26]. Thus, suitable control genes are extremely
specific for particular sample sets and experimental
models, being a crucial component in assessing gene
expression patterns with confidence. Striking examples
are provided by the glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) and beta-actin genes, which have been
extensively used for normalization of gene expression data
in a broad range of different tissues and pathologies, in-
cluding the nervous system [25-28]. It has been shown
however, that GAPDH and beta-actin genes are indeed
direct targets of miR-644a in prostate cancer cell lines,
demonstrating the unsuitability of GAPDH and beta-actin
as internal controls in miR-644a functional studies and
emphasizing the need to carefully consider the choice of a
reference gene according to the specific study design [29].
Small nuclear RNAs as well as miRNAs and snoRNAs
are widely used as reference genes for miRNA studies in
tissue samples and blood. To date, in the field of the
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ation of a set of reliable reference genes for a miRNA pro-
filing study in blood PD samples.
For that reason, the present study aims not only to
identify and to validate specific endogenous reference
genes as reported in the literature, but also to evaluate
the impact of the use of different combinations of these
reference genes on the interpretation of expression pro-
file differences between cases and controls of certain tar-
get miRNAs.
We selected from the literature the most commonly
used reference genes in qRT-PCR blood studies or in
neurological diseases studies. We then assessed their
suitability as normalizers, and their effect, alone or in
combination, on the target genes miR-30b-5p and miR-
29a-3p in PD blood samples, previously shown to have
altered expression profiles in PD [7,8]. The selection of
the best set of endogenous reference genes for gene ex-
pression studies in Parkinson’s disease blood samples
from those tested was based on the efficiency of the
TaqMan® MicroRNA Assays, the quality of the related
expression data, on the expression stability analysis,
and biological data available in the literature.
Using these metrics of efficiency, quality and stability,
RNU24 ranks top of the list, followed by Z30 as the best
reference genes in our study. Moreover, neither RNU24
nor Z30 have been related so far to neurodegeneration
and/or Parkinson’s disease. On the contrary, miR-103a-3p
is ranked as the worst reference gene, so much so that
in combination with other reference genes it is able to
bias results.
It is important to underline that miR-103a-3p alone or
in combination with the other reference genes reverses
the direction of the expression of miR-29a-3p and miR-
30b-5p. Our results are consistent with the available
literature evidence, which support the unsuitability of
miR-103a-3p as a reference gene in PD studies for a num-
ber of reasons. MiR-103a-3p and miR-107 have been re-
cently shown to target human CDK5R1 [30], coding for
the regulatory subunit 1 of cyclin-dependent kinase 5, a
protein found to be hyperactivated in different neurode-
generative diseases, including Parkinson’s and Alzheimer's
diseases [31,32]. The same two miRNAs have also been
shown to regulate insulin sensitivity by targeting caveolin-
1 [33]. The connection between miR-103a-3p and insulin
is relevant, since insulin is known to regulate dopamine
release. Moreover, in a recent study a correlation between
PD and a hyperglycaemic status was shown in rats [34].
Last, but not of minor importance when studying neuro-
degenerative disease, is the evidence that the expression of
miR-103a-3p varies depending on the age of the patients
[35]. In our study, the paired case–control experimental
design allows correction for the confounding effect of age,
but adjustment for age would be required for unmatcheddesigns. This may be unfeasible for small qRT-PCR studies,
therefore the confounding effect would not be controlled
and the results would be biased.
Contrary to miR-103a-3p, the insertion of RNU6B in
combinations with other reference genes has a lower im-
pact on the stability values, but we hypothesize that this
effect can be attributed to the high stability of RNU24
and Z30. RNU6B was not considered to be a reliable refer-
ence gene for PD blood samples in our study, because the
efficiency, the r2 and the stability values were too low. Fur-
thermore, in support of this conclusion, RNU6B has been
shown to be stable under some but not all conditions of
neuronal differentiation [36].
Conclusion
In conclusion, the results of this study indicate that rela-
tive expression differences of the selected microRNAs
between Parkinson’s cases and controls were profoundly
affected by the choice of the reference gene set, thus
demonstrating the complexity of the choice of reference
gene set. A real endogenous reference gene should be
stably expressed, regardless of physiological conditions,
including age and disease. In our hands, using miR-103a-
3p as a reference gene, alone or in combination with other
suitable genes, produced contrasting results within our
dataset. Our data suggest that RNU24 and Z30 constitute
a reference gene set that will lead to reliable data for
normalization of miRNA expression profiles in blood of
PD patients versus controls, at least until new technolo-
gies for direct PCR quantification such as droplet-digital
PCR become more widespread and affordable. The results
confirm the importance of a careful choice of the refer-
ence genes, which should be evaluated depending on the
specific on-going study, not relying solely on evidence
already published.
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